Surgery Name Chronic Kidney Disease Review

Review Status: Review Required (CKD Stage 1-2 with >1 year since last eGFR or ACR >3)

Current EMIS Status: Chronic Kidney disease stage 3

Results Overview

Patient Information

NHS Number: 168890Age: 75 | Gender: Female

CKD Overview

• Stage: Stage 2 | ACR criteria: A2

• Albumin-Creatinine Ratio (ACR): 20.4 mg/mmol

• Creatinine:

Current: 86 μmol/L | Date: 2023-10-07
3 Months Prior: 0 μmol/L | Date: nan

• eGFR:

Current: 60 ml/min/1.73m² | Date: 2023-10-07
 3 Months Prior: 0 ml/min/1.73m² | Date: nan

• Anaemia Overview:

• Haemoglobin: 126 g/L | Date: nan

• Current Status: Normal

• Anaemia Management: No Action Needed

Electrolyte and Mineral Bone Disorder (MBD) Management

Potassium: 4.3 mmol/L | Status: Normal | Date: nan
 Phosphate: 1.43 mmol/L | Status: Normal | Date: nan
 Calcium: 2.15 mmol/L | Status: Hypocalcemia | Date: nan

MBD Status: Check CKD-MBD
 Vitamin D Level: 33 ng/mL | Date: nan

• Vitamin D Status: Normal

Blood Pressure

Classification: Normal | Date: nan
 Systolic / Diastolic: 118 / 75 mmHg

• Target BP: <130/80 | BP Status: On Target

Kidney Failure Risk

2-Year Risk: N/A%5-Year Risk: N/A%

The patient's 2- and 5-year kidney failure risk scores estimate the likelihood that their kidney disease will progress to kidney failure within the next 2 or 5 years. These scores are calculated based on the patient's current kidney function and other risk factors such as age, blood pressure, and existing health conditions. Understanding these risk scores helps in predicting disease progression and planning appropriate treatment strategies.

Care & Referrals

Multidisciplinary Care: Not Indicated
 Modality Education: Not Indicated
 Nephrology Referral: Not Indicated

• Persistent Proteinuria: Persistent Proteinuria - Consider Referral

Medication Review

• Current Medication: Omeprazole 20mg

• Review Medications: No adjustments needed

• Contraindicated Medications: No contraindications

• **Suggested Medications:** Statin (e.g., Atorvastatin, Rosuvastatin, Simvastatin), ACE inhibitors (if not contraindicated) for proteinuria (if indicated), Lifestyle modifications

• Statin Recommendation: Not on Statin

Diabetes and HbA1c Management

HbA1c Level: 43 mmol/mol | Date: nan
 HbA1c Management: On Target

Lifestyle and Preventative Advice

Lifestyle Recommendations: Encourage a balanced diet, including reduced sodium intake. Promote regular
physical activity (150 minutes per week) as per general health guidance. Emphasize smoking cessation and
maintaining a healthy weight.

NICE Guideline Recommendations

CKD Stage G2 Recommendations:

- **Initial Assessment:** Repeat Urine ACR testing, haematuria screening, and BP monitoring as per Stage G1. Confirm stable renal function by reviewing previous eGFR results or retest within 14 days if necessary.
- Management and Monitoring: Continue primary care management with annual monitoring if ACR is greater than 3 mg/mmol. Reduce monitoring frequency if ACR is less than 3 mg/mmol and no additional risk factors are present.
- Lifestyle and Preventive Measures: Promote lifestyle interventions such as regular exercise, smoking cessation, and weight management. Maintain BP targets of less than 140/90 mmHg, or less than 130/80 mmHg for patients with diabetes or significant proteinuria (ACR >70 mg/mmol).
- **Medication:** Evaluate cardiovascular risk and consider statin therapy as per guidelines. If proteinuria is present, consider initiating an ACE inhibitor or angiotensin receptor blocker (ARB) to reduce proteinuria and slow CKD progression.

Surgery Name, Add 1, Add 2, Belfast, BT123456

Telephone: 028 90*********